CO5450246A1 - VACCINE - Google Patents
VACCINEInfo
- Publication number
- CO5450246A1 CO5450246A1 CO00052321A CO00052321A CO5450246A1 CO 5450246 A1 CO5450246 A1 CO 5450246A1 CO 00052321 A CO00052321 A CO 00052321A CO 00052321 A CO00052321 A CO 00052321A CO 5450246 A1 CO5450246 A1 CO 5450246A1
- Authority
- CO
- Colombia
- Prior art keywords
- protein
- seq
- prostase
- vaccine
- fusion
- Prior art date
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Una proteína de fusión que incluye una proteína prostasa, fragmento u homologos de la misma, unida a un acompañante heterológo de fusión. Una proteína de acuerdo con la reivindicación 1, en la que el antígeno prostasa se selecciona del grupo formado por la SEQ ID N° 5, SEO ID N° 6, SEQ ID N° 7 y SEQ ID N° 8.1 Una vacuna de acuerdo con la reivindicación 10 u 11, en la que el adyuvante comprende 3D-MPL, QS21, un oligonucleótido CpG o un éter o éster de polietileno.1 Uso de una proteína o de un ácido nucleico de acuerdo con las presentes reivindicaciones, para la fabricación de una vacuna para tratar inmunoterapéuticamente un paciente que padece cáncer u otros tumores asociados con una prostasa.A fusion protein that includes a prostase protein, fragment or homologs thereof, attached to a fusion heterolologous companion. A protein according to claim 1, wherein the prostase antigen is selected from the group consisting of SEQ ID No. 5, SEO ID No. 6, SEQ ID No. 7 and SEQ ID No. 8.1 A vaccine according to claim 10 or 11, wherein the adjuvant comprises 3D-MPL, QS21, a CpG oligonucleotide or a polyethylene ether or ester. 1 Use of a protein or a nucleic acid according to the present claims, for the manufacture of a vaccine to immunotherapeutically treat a patient suffering from cancer or other tumors associated with a prostase.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/352,616 US6395278B1 (en) | 1997-02-25 | 1999-07-13 | Prostate specific fusion protein compositions |
| US09/439,313 US6329505B1 (en) | 1997-02-25 | 1999-11-12 | Compositions and methods for therapy and diagnosis of prostate cancer |
| US44368699A | 1999-11-18 | 1999-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5450246A1 true CO5450246A1 (en) | 2004-10-29 |
Family
ID=40913635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00052321A CO5450246A1 (en) | 1999-07-13 | 2000-07-12 | VACCINE |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2009142284A (en) |
| CO (1) | CO5450246A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3828545B1 (en) * | 2018-10-04 | 2024-01-24 | Otsuka Pharmaceutical Co., Ltd. | Method for acquiring auxiliary information |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262245B1 (en) * | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| CO4870792A1 (en) * | 1997-02-25 | 1999-12-27 | Corixa Corp | COMPOUNDS AND SET OF DIAGNOSTIC MEANS TO DETECT AND MONITOR THE PROGRESSION OF CANCER OF PROSTATE |
| US6130043A (en) * | 1997-05-02 | 2000-10-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| CA2331769A1 (en) * | 1998-06-22 | 1999-12-29 | Incyte Pharmaceuticals, Inc. | Prostate cancer-associated genes |
-
2000
- 2000-07-12 CO CO00052321A patent/CO5450246A1/en not_active Application Discontinuation
-
2009
- 2009-01-29 JP JP2009017430A patent/JP2009142284A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009142284A (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials | |
| BR9812472A (en) | Specific mamaglobin vaccine, process to treat a patient with a tumor that expresses mamaglobin, and isolated and purified polypeptide | |
| PT1053325E (en) | ANTIGEN DERIVATIVES ASSOCIATED WITH MAGE FAMILY TUMORS, AND SEQUENCES OF NUCLEIC ACIDS THAT ENCODE THEM, USED FOR THE PREPARATION OF FUSAO PROTEINS AND VACCINATION COMPOUNDS. | |
| CY1106103T1 (en) | METHOD FOR SEPARATION OF ROTAI VARIANTS AND LIVE ATTENUATED ROTAI VACCINE | |
| PE20050712A1 (en) | RG1 ANTIBODIES | |
| TR200002731T2 (en) | Methods for the identification, composition and use of inductors and inhibitors of proteolytic antibodies | |
| WO2002022686A3 (en) | Defensin-antigen fusion proteins | |
| PT1047446E (en) | VACCINE COMPOSITION FOR HERPES SIMPLEX VIRUS AND METHODS OF USE | |
| ATE286745T1 (en) | USE OF ANTIBODIES FOR VACCINATION AGAINST CANCER | |
| CY1105179T1 (en) | DRUGS FOR THE IMMUNE TREATMENT OF MALIGNANT TUMORS | |
| JP2003530088A5 (en) | ||
| JP2002534481A5 (en) | ||
| CO5450246A1 (en) | VACCINE | |
| WO2001035989A3 (en) | Use of anti-idiotypical antibodies as vaccines against cancer | |
| AR036793A1 (en) | NUCLEIC ACID VACCINES USING NUCLEIC ACIDS THAT CODIFY A TUMOR ANTIGEN WITH A NUCLEIC ACID CODIFYING A CYTOKIN AS AN ADJUTIVE | |
| DK0889969T3 (en) | Recombinant adenoviral for gene therapy of human tumors | |
| PT1272652E (en) | HERPES VIRUS FOR IMMUNITY MODULATION | |
| UY26266A1 (en) | ANTIGEN ASSOCIATED WITH TUMORS (R11) LAW 17164 | |
| ATE234628T1 (en) | THERAPEUTIC APPLICATIONS OF ANTIGENS OR EPITOPES ASSOCIATED WITH INCOMPLETE CELLULAR PEPTIDE PROCESSING, E.G.: EXPRESSED IN RMA-S CELLS TRANSFECTED WITH B7-1 GENE | |
| WO2002022687A3 (en) | Viral chemokine-tumur antigen fusion proteins | |
| DE69922804D1 (en) | USE OF POLYMERS OF HYALURONIC ACID FOR THE MUCOSAL RELEASE OF VACCINES AND ADJUVANTIES | |
| WO2004098529A3 (en) | Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules | |
| CO5280140A1 (en) | ANTIGEN (C42) ASSOCIATED WITH TUMORS | |
| AR023794A1 (en) | ANTIGEN ASSOCIATED WITH TUMORS | |
| CY1113516T1 (en) | NUCLEAR ACID AND CORRESPONDING PROTEIN 158P1D7 USEFUL IN TREATMENT AND DETECTION OF CANCER URBAN AND OTHER CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |